Innovare Academic Sciences

International Journal of Pharmacy and Pharmaceutical Sciences ISSN- 0975-1491

Vol 7, Issue 9, 2015

Original Article

DETERMINATION OF ATORVASTATIN CALCIUM IN PURE AND ITS PHARMACEUTICAL FORMULATIONS USING IODINE IN ACETONITRILE BY UV-VISIBLE SPECTROPHOTOMETRIC METHOD ABDUL AZIZ RAMADAN1*, HASNA MANDIL2, JENAN SABOUNI Department of Chemistry, Faculty of Science, University of Aleppo, Syria Email: [email protected] Received: 21 May 2015 Revised and Accepted: 28 Jul 2015 ABSTRACT Objective: A simple, sensitive and specific spectrophotometric method was developed for the determination of atorvastatin calcium (ATCa) in pure and its pharmaceutical formulations using iodine in acetonitrile. Methods: The method is based on the oxidation of atorvastatin calcium by iodine and formation triiodide (I3−) complex.

Results: The formed complex was measured at 291 and 360 nm against the reagent blank prepared in the same manner. The optimum experimental parameters are selected. Beer’s law is valid within a concentration range of 0.5586-11.173 μg/ml. The relative standard deviation did not exceed 3.0% and regression analysis showed a good correlation coefficient (R2= 0.9995). The limit of detection (LOD) and the limit of quantification (LOQ) were to be 0.056 and 0.17 μg/ml, respectively. Conclusion: The developed method is applied for the determination of atorvastatin in pure and its commercial tablets without any interference from excipients (at λmax =291 & 360 nm), ezetimibe (EZE), fenofibrate (FEN) and aspirin (ASP) at λmax =360 nm with average recovery of 99.45 to 102.4%. The results obtained agree well with the contents stated on the labels. Keywords: Spectrophotometric method, Atorvastatin calcium (ATCa), Iodine, Triiodide complex. INTRODUCTION Atorvastatin calcium is a calcium (bR, dR)-2-(r-fluorophenyl)-b, ddihydroxy-5-isopropyl-3-phenyl-4-(phenylcarbamoyl) pyrrole-1hepatanoicacid (1:2) trihydrate. The empirical formula of atorvastatin calcium trihydrate is C66H68CaF2N4O10.3H2O or (C33H34FN2O5)2Ca.3H2O, mol. mass 1209.4 g; where the empirical formula of atorvastatin is C33H35FN2O5, mol. mass 558.64 g (Scheme1) [1]. Atorvastatin calcium is a white to off-white crystalline powder that is insoluble in aqueous solutions of pH 4 and below. Atorvastatin calcium is very slightly soluble in distilled water, pH 7.4 phosphate buffer and acetonitrile; slightly soluble in ethanol; and freely soluble in methanol. Atorvastatin is a member of the drug class known as statins, used for lowering blood cholesterol. It also stabilizes plaque and prevents strokes through anti-inflammatory and other mechanisms [2, 3]. Several studies have been reported for

Atorvastatin C33H35FN2O5, AT

the determination of atorvastatin in pure form, in pharmaceutical formations and in biological fluids including spectrophotometric methods [2, 4-36], chromatographic methods with different detectors [37-39] and electrochemical methods analysis [40-49].

Spectrophotometric determination of rosuvastatin calcium through oxidation it by iodine and formation I3− complex in acetonitrile was studied. It was found that only one molecule of rosuvastatin, from two molecules of RSV in (RSV)2 Ca, ionized and oxidized by iodine [36]. In chemistry, triiodide usually refers to the triiodide ion, I3− (Scheme2). This anion, one of the polyhalogen ions, is composed of three iodine atoms. It is formed by combining non-aqueous and aqueous solutions of iodide salts and iodine according to the following equation [50-57]: I–+I2 → I3– ……………………………………………………………….. (1)

Atorvastatin calcium(C33H34FN2O5)2Ca.3H2O, ATCa

Scheme 1: Chemical structure of atorvastatin and atorvastatin calcium

Scheme 2: Chemical structure of triiodide, I3Many pharmaceutical preparations of AT contain another drug as ezetimibe (EZE), fenofibrate (FEN) and Aspirin (ASP) in the combined dosage forms. In the present work, we developed (for the first time) a specific spectrophotometric method allows determination of atorvastatin calcium in the presence of some other drugs as EZE, FEN and ASP by oxidizing it with iodine and formation I3–complex in acetonitrile.

Ramadan et al.

Int J Pharm Pharm Sci, Vol 7, Issue 9, 427-433

MATERIALS AND METHODS

Working standard addition solutions of pharmaceuticals

Instruments and apparatus

These solutions were prepared as the follows: same mentioned volumes of stock solutions of pharmaceuticals were taken with 0.40, 0.80, 1.20 and 1.60 ml from stock solution (b) of atorvastatin and then 0.5 ml from stock standard solution of iodine was added and diluted to 10 ml with acetonitrile. These solutions contain 2.000 μg/ml of atorvastatin (from different pharmaceuticals) plus 2.2346, 4.469, 6.7037 and 8.938 μg/ml of standard atorvastatin, respectively.

Spectrophotometric measurements were made in PG Instruments Ltd model UV-Visible spectrometer T90+with 0.5 cm quartz cells. An ultrasonic processor model POWERSONIC 405 was used to sonicate the sample solutions. The solution was kept in a thermostat at 35oC. The diluter pipette model DIP-1 (Shimadzu), having 100 μl sample syringe and five continuously adjustable pipettes covering a volume range from 20 to 5000 μl (model PIPTMAN P, GILSON). A centrifuge (Centurion Scientific Ltd., Model: K2080-Manufactured in the United Kingdom) was used for preparation of the experimental solutions. Reagents

Atorvastatin Calcium trihydrate was supplied by ind-swift (India), its purity as atorvastatin was 92.0%. Iodine (purity 99.8%) of analytical grade, acetonetrile for HPLC and methanol extra pure was from MERCK. All solvents and reagents were analytical grade chemicals. A stock standard solution of iodine (1x10-2 mol/l)

Dissolving 63.58 mg of iodine with acetonitrile into volumetric flask (25 ml) and diluting to mark by acetonitrile. A stock standard solution of atorvastatin calcium (1x10-4 mol/l)

This solution was prepared by dissolving 32.86 mg from atorvastatin calcium trihydrate in 1 ml methanol and diluting to 50 ml with acetonitrile, 1x10-3 mol/l of atorvastatin (a), then diluting 5.000 ml from this solution to 50 ml with acetonitrile, 1x10-4 mol/l of atorvastatin (b). The stock solutions were further diluted to obtain working solutions daily just before the use in the ranges of atorvastatin: 1, 2, 4, 6, 8, 10, 12, 16, and 20 μmol/l (0.5586, 1.117, 2.234, 3.352, 4.469, 5.586, 6.704, 8.9386 and 11.173 μg/ml) by transferring the volumes: 0.1, 0.2, 0.4, 0.6, 0.8, 1.0, 1.2, 1.6 and 2.0 ml from stock standard solution (b) into volumetric flask (10 ml), then adding 0.5 ml from stock standard solution of iodine and diluting to 10 ml with acetonitrile.

Procedure

A 10 ml volume of a solution containing an appropriate concentration of atorvastatin (or working solutions of pharmaceuticals or working standard addition solutions of pharmaceuticals) with appropriate amount of iodine in acetonitrile was kept at temperature 35±5 °C for 20 min at λmax,1= 291 nm and at λmax,2= 360 nm was ready for spectrophotometric measurement. RESULTS AND DISCUSSION

The different experimental parameters affecting on the spectrophotometric determination of atorvastatin calcium through oxidation it by iodine and formation I3− complex in acetonitrile were extensively studied in order to determine the optimal conditions for the determination of AT. Spectrophotometric results

UV-Vis spectra of ATCa, Iodine, I3–complex (resulting from the oxidation of ATCa by iodine), ezetimibe (EZE), fenofibrate (FEN) and aspirin (ASP) solutions in acetonitrile were studied. The ATCa, EZE, FEN and ASP solutions do not absorb in range 340-600 nm, the values of λmax for them were 246, 220, 287 and 226 nm, and of molar absorptivity (ε) were 2.33x104, 2.75x104, 2.58x104 and 0.75x104 L. mol-1. cm-1, respectively. The iodine solutions absorb at λmax 456 nm (ε=830 L. mol-1. cm-1), while complex solutions of I3–have absorption at λmax,1 = 291 nm and λmax,2=360 nm (ε291=4.645x104 L. mol-1. cm-1 and ε360=2.23x104 L. mol-1. cm-1). See fig. 1.

Sample preparation

A commercial formulation (as tablet) was used for the analysis of atorvastatin. The pharmaceutical formulations subjected to the analytical procedures:

(1) Ezerva tablets, Barakat pharmaceutical industries, Aleppo-Syria, each tablet contains: 10 mg of atorvastatin (AT) and 10 mg of ezetimibe (EZE).

(2) Normostat tablets, Barakat pharmaceutical industries, AleppoSyria, each tablet contains: 20 mg of AT.

(3) Atorvatin tablets, Alpha, Aleppo pharmaceutical industries, Aleppo-Syria, each tablet contains: 10, 20 and 40 mg of AT.

4) Fibator tablets, Sun Pharma, India, each tablet contains: 5 and 145 mg of AT and fenofibrate (FEN), respectively. Stock solutions of pharmaceutical formulations

20 tablets of each studied pharmaceutical formulation were weighted accurately, crushed to a fine powder and mixed well. A quantity of the powder equivalent to tenth of the weight of one tablet, was solved in 1 ml methanol by using ultrasonic, 10 ml of acetonitrile was added, filtered over a 50 ml flask and washed by the same solvent, then diluted to 50 ml with acetonitrile. This solution contains the follows: 20, 40 and 80 μg/ml for all studied pharmaceutical formulations contain 10, 20 and 40 mg/tab, respectively. Working solutions of pharmaceuticals

These solutions were prepared daily by diluting 1.00, 0.50 and 0.25 ml from stock solutions of pharmaceutical formulations, respectively, then adding 0.5 ml from stock standard solution of iodine and adjusting the volume to 10 ml with acetonitrile (each solution contains 2 μg/ml of atorvastatin).

Fig. 1: UV-Vis spectra in acetonitrile of: 1-2.0x10-5 mol/l of AT; 2-5x10-4 mol/l of I2; 3,4-2.0x10-5 mol/l of AT with 5x10-4 mol/l of I2 (where the complex I3–is formed); 5-7: 2.0x10-5 mol/l of EZE, FEN and ASP, respectively. { blank is acetonitrile (1-3 & 5-7) and iodine solution 5x10-4 mol/l (4), ℓ =0.5 cm} The effect of temperature and time The effect of temperature and time on the studied spectrophotometric method of AT was studied at different values 20-40 oC and 5-60 min. It was found that the value of the absorbance (A) was not affected by temperature between 30 to 40oC (the temperature 35±5 °C was used). The effect of waiting time was determined at temperature (35 °C). It was found that the value of (A) was not affected by time between 18 to 30 min (the waiting time 20 min was used). The optimum parameters established for determination of AT are shown in table 1. 428

Ramadan et al.

Int J Pharm Pharm Sci, Vol 7, Issue 9, 427-433

Table 1: The optimum parameters established for spectrophotometric determination of AT through oxidation ATCa by iodine and formation I3− complex in pure and pharmaceutical dosage forms in acetonitrile parameters Waiting time Temperature of solution CI2:CAT, M Solvent λmax,1 of complex λmax,2 of complex I3− λmax of atorvastatin Molar absorptivity of complex I3− (ε1) Molar absorptivity of complex I3− (ε2) Molar absorptivity of AT (εAT) Working λmax,1 Working λmax,2 ℓ Spectra range Working CI2, mol/l Beer’s Law Limit, μg/ml LOD(3.3SD), μg/ml LOQ (10SD), μg/ml Regression equation at λmax,1=291 nm: Slope Intercept Correlation coefficient (R2) Regression equation at λmax,2=360 nm: Slope Intercept Correlation coefficient (R2) RSD% at λmax,1=291 nm RSD% at λmax,2=360 nm

Operating modes 20 min 35±5 °C ≥10 Acetonitrile 291 nm 360 nm 246 nm 4.645x104 L. mol-1. cm-1 2.23x104 L. mol-1. cm-1 2.33x104 L. mol-1. cm-1 291 nm 360 nm 0.5 cm 200–600 nm 5x10-4 0.5586–11.173 0.056 0.17 0.0837 0.0024 0.9995 0.0390 0.0018 0.9992 3.0 3.4

The effect of iodine concentration

I3–

The effect of iodine concentration on the absorbance of formed through oxidation atorvastatin calcium by iodine was studied. It was found that the absorbance increased with increasing the ratio of CI2:CAT from 1:1 to 5:1 then stayed constant (the ratio CI2: CAT≥10 was used, see table 1). i-The first step

Mechanism of oxidation atorvastatin calcium by iodine in acetonitrile We suggest that the mechanism of oxidation atorvastatin calcium by iodine and formation I3− complex in acetonitrile may take place according to the equations (Scheme 2), as the follows: Calibration curves

The calibration curves for atorvastatin in pure form through oxidation ATCa by iodine and formation I3− complex showed excellent linearity over the concentration range of 1x10-6 to 2.0x10-5 mol/l (0.5586-11.173 μg/ml), see fig. 2 and 3. The spectra characteristics of determination of ATCa solutions such as the molar absorptivity (ε), λmax, Beer's law, regression equations which are at λmax,1=291 nm y=0.0837x+0.0024 and at λmax,2=360 nm y=0.0390x+0.0018; where y=absorbance, x=concentration of AT in μg/ml and the correlation coefficient are summarized in table 1. Analytical results

Spectrophotometric determination of AT through oxidation atorvastatin calcium by iodine and formation I3− complex within optimal conditions using calibration curve was applied. The results, which are summarized in table 2, showed that the determined concentration of AT was rectilinear over the range of 0.5586 to 11.173 μg/ml with relative standard deviation (RSD) was not more than 3.0%. (2) ii-The second step: 4I-+4I2 → 4I3-

iii-The proceeds equation:

(3)

[AT]2Ca+6I2 → [5-Oxo-AT]2 Ca+4I3-+4H+(4)

Scheme 2: Mechanism of oxidation atorvastatin calcium by iodine and formation I3− complex

The limit of detection (LOD) and limit of quantification (LOQ) were found to be 0.056 μg/ml and 0.17 μg/ml, respectively. The proposed method was validated statistically and through recovery studies. The method was successfully applied for the determination of AT in pure form. The results obtained from the proposed method have been compared with the official RP-HPLC method [37] and good agreement was found between them. Repeatability

The repeatability of the method was evaluated by performing 10 repeat measurements for 8.936 μg/ml of AT using studied spectrophotometric method under the optimum conditions. The amount of AT was found to be 8.872±0.26 µg/ml and the percentage 429

Ramadan et al.

Int J Pharm Pharm Sci, Vol 7, Issue 9, 427-433

recovery was found to be 98.79±2.4 with RSD of 0.026. These values indicate that the proposed method has high repeatability and precision for AT analysis.

Fig. 2: UV-Vis spectra of 5x10-4 mol/l iodine with AT at concentrations as the follows: 1-0.0, 2-1.0x10-6; 3-2.0x10-6; 44.0x10-6; 5-6.0x10-6; 6-8.0x10-6; 7-1.00x10-5; 8-1.20x10-5; 91.60x10-5and 10-2.00x10-5 mol/l in acetonitrile { Blank: (a) acetonitrile and (b) iodine solution 5x10-4 mol/l, ℓ =0.5 cm}

Fig. 3: Calibration curve for determination of AT through oxidation ATCa by I2 and formation I3− complex according to optimal conditions at λmax: 1-291 nm and 2-360 nm (Blank is iodine solution 5x10-4 mol/l, ℓ = 0.5 cm)

Table 2: Spectrophotometric determination of AT through oxidation atorvastatin calcium by iodine and formation I3− complex within optimal conditions using calibration curve in acetonitrile Xi, μg/ml (taken)

0.5586 1.117 2.234 3.352 4.468 5.586 6.704 8.936

11.173 *

n=5, t= 2.776.

λmax, nm 291 360 291 360 291 360 291 360 291 360 291 360 291 360 291 360 291 360

x

, * μg/ml (found) 0.569 0.550 1.120 1.168 2.182 2.271 3.376 3.265 4.332 4.369 5.706 5.693 6.662 6.797 8.872 8.784 11.262 11.256

SD, μg/ml

0.017 0.019 0.034 0.040 0.063 0.077 0.094 0.11 0.12 0.15 0.15 0.19 0.17 0.22 0.21 0.26 0.25 0.31

APPLICATION Many applications for the determination of atorvastatin calcium in some pharmaceutical preparations (which contain ATCa only or ATCa with EZE or FEN or ASP) using spectrophotometric method (at λmax,1 = 291 nm and λmax,2 = 360 nm) through oxidizing it by iodine and formation I3–complex in acetonitrile according to the optimal conditions were performed. Regression equations and correlation coefficients were included in table 3. Standard additional curves for determination of atorvastatin calcium in different pharmaceutical preparations were used. The standard addition curves of Atorvatin, tablets (Alpha 10 mg/tab.) and Ezerva, tablets (Barakat 10 mg/tab. of AT and 10 mg/tab. of EZE) were shown in fig. 4, as an example. The amount (m) of atorvastatin calcium in one tablet was calculated from the following relationship: m = h. m', where: m' is the amount

SD n , μg/ml 0.0076 0.0084 0.015 0.018 0.028 0.035 0.042 0.050 0.054 0.066 0.069 0.084 0.077 0.097 0.095 0.12 0.11 0.14

x±

t .SD

RSD %

x , μg/ml RP-HPLC [37]

3.0 3.4 3.0 3.4 2.9 3.4 2.8 3.4 2.8 3.4 2.7 3.3 2.6 3.2 2.4 3.0 2.2 2.8

0.557

n μg/ml 0.569±0.021 0.55±0.023 1.12±0.042 1.168±0.049 2.182±0.079 2.271±0.099 3.376±0.12 3.265±0.14 4.332±0.15 4.369±0.18 5.706±0.19 5.693±0.23 6.662±0.21 6.797±0.27 8.872±0.26 8.784±0.33 11.262±0.31 11.256±0.39

1.115 2.240 3.362 4.436 5.585 6.700 8.901

11.198

of AT in tablet calculated according to the following regression equation: y=a.x+b; when y=0; m'=x=b/a=intercept/slope (μg/ml), h conversion factor is equal to 5, 10 and 20 for 10, 20 and 40 mg/tab of AT. The results of quantitative analysis for AT in some pharmaceutical preparations calculated using the standard additions method were summarized in table 4. Many pharmaceutical preparations of AT contain another drug as EZE, FEN and ASP in combined dosage forms. It was found that λmax,1 could be used if preparation contains only AT, where λmax,2 should be used for preparations contain EZE or FEN or ASP with AT. The proposed method was simple, economic, specific and successfully applied to the determination of AT in pharmaceuticals (at λmax,2 = 360 nm) without any interference. Average recovery was 99.45 to 102.4%. The results obtained by this method agree well with the contents stated on the labels and were validated by RP-HPLC [37].

430

Ramadan et al.

Int J Pharm Pharm Sci, Vol 7, Issue 9, 427-433

Table 3: Regression equations and correlation coefficients for determination of AT (individually or with EZE or FEN) in some pharmaceutical preparations using developed spectrophotometric method in acetonitrile at λmax291 nm and 360 nm Commercial name Ezerva

Contents, mg/tab. AT EZE FEN 10 10 -

Atorvatin

10

Normostat

Fibator

*y=

20

-

-

20

-

-

40 5

-

-

145

λmax, nm 291 360 291 360 291 360 291 360 291 360 291 360

m'(AT), Regression μg/ml equations* 2.357 y=0.0846x+0.1994 2.047 y=0.0400x+0.0819 2.043 y=0.0832x+0.1700 2.033 y=0.0394x+0.0801 1.991 y=0.0839x+0.1670 1.989 y=0.0397x+0.0790 2.045 y=0.0834x+0.1705 2.020 y=0.0389x+0.0786 2.012 y=0.0838x+0.1686 2.006 y=0.0391x+0.0784 Not determined 2.035 Y=0.0396x+0.0806

n A, x= concentration of atorvastatin (µg/ml)= m' = intercept/slope.

Correlation coefficients

Amount of AT (m), mg/tab.

R2=0.9993 R2=0.9991 R2=0.9994 R2=0.9994 R2=0.9994 R2=0.9986 R2=0.9994 R2=0.9994 R2=0.9994 R2=0.9994

mAT/tab.=5m'=11.78 mAT/tab.=5m'=10.24 mAT/tab.=10m'=20.43 mAT/tab.=10m'=20.33 mAT/tab.=5m'=9.955 mAT/tab.=5m'=9.945 mAT/tab.=10m'=20.45 mAT/tab.=10m'=20.20 mAT/tab.=20m'=40.24 mAT/tab.=20m'=40.12

R2=0.9982

mAT/tab.=2.5m'=5.09

Table 4: Determination of AT in some pharmaceutical preparations using spectrophotometric method through oxidation atorvastatin calcium by iodine and formation I3− complex in acetonitrile λmax291 nm and 360 nm Commercial name

Contents, mg/tab. AT EZE FEN

Ezerva

10

10

-

Atorvatin

10

-

-

Normostat

Fibator

* n=5

20 20 40 5

-

-

145

λmax, nm 291 360 291 360 291 360 291 360 291 360 291 360

RSD%

*x , mg/tab.

11.78 3.6 10.24 3.7 20.43 3.6 20.33 3.7 9.955 3.6 9.945 3.7 20.45 3.5 20.20 3.6 40.24 3.4 40.12 3.5 Not determined 5.09 3.9

Recovery %

RP-HPLC [37]

x , mg/tab

RSD%

117.8 102.4 102.2 101.7 99.55 99.45 102.3 101.0 100.6 100.3

10.20

2.1

9.940

2.0

101.8

20.41 20.21 40.00 5.10

1.8 1.8 1.7 2.2

CONCLUSION A simple, sensitive and specific spectrophotometric method is developed for the determination of atorvastatin calcium in pure and its pharmaceutical formulations in acetonitrile. This method is based on the oxidation of atorvastatin calcium by iodine and formation I3− complex. The formed complex was measured at 291 and 360 nm against the reagent blank prepared in the same manner. The optimum experimental parameters are selected. Beer’s law is valid within a concentration range of 0.5586-11.173 μg/ml. The developed method is applied for the determination of atorvastatin in pure and its commercial tablets without any interference from excipients (at λmax =291 & 360 nm), ezetimibe, fenofibrate and aspirin (at λmax =360 nm) with average recovery of 99.45 to 102.4%. The results obtained agree well with the contents stated on the labels and were validated by RP-HPLC [37]. CONFLICT OF INTERESTS

The authors have declared that no conflict of interests exists REFERENCES 1. Fig. 4: The standard addition curve for determination of AT in Atorvatin, Alpha 10 mg/tab. AT only(1 and 2) and in Ezerva, Ctd. tab., Barakat, 10 mg/tab. AT and 10 mg/tab. EZE (3 and 4) using developed spectrophotometric method in acetonitrile at λmax=291 nm (1 & 3) and 360 nm (2 & 4), ℓ = 0.5 cm

2. 3.

Reents S, Seymour J. Clinical Pharmacology: An Electronic Reference and Teaching Guide CD-ROM, Gold Standard Multimedia Inc., Tampa, FL; 1998. Ramesh D, Ramakrishna S. New spectrophotometric methods for simultaneous determination of amlodipine besylate and atorvastatin calcium in tablet dosage forms. Int J Pharm Pharm Sci 2010;2:215-9. Smita T Kumbhar, Swapnil D Jadhav, Neela M Bhatia, Manish S Bhatia. Development and validation of derivative spectrophotometric method for estimation of atorvastatin 431

Ramadan et al.

4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22.

calcium and amlodipine besylate in tablet dosage form. Int J Pharm Pharm Sci 2011;3:195. Erk N. Extractive spectrophotometric determination of atorvastatin in bulk and pharmaceutical formulations. Marcel Dekker 2003;36:2699–11. Muthu AK, Gupta TR, Sharma S, Smith AA, Manavalan R, Kannappan N. Simultaneous estimation of amlodipine and atorvastatin in tablets using orthogonal Function ratio spectrometry. Int J Chem Sci 2008;6:2233-41. Nagaraju P, Pasumarthy, Gopal NV, Srinivas VDN, Padma SVN. Spectrophotometric methods for the determination of atorvastatin calcium in pure and it’s pharmaceutical dosage forms. Asian J Res Chem 2008;1:64-6. Baldha RG, Vandana BP, Bapna M. Simultaneous spectrophotometric determination of atorvastatin calcium and ezetimibe in tablet dosage form. Int J Chem Tech Res 2009;1:233-6. Shravya A, Chandan RS, Gurupadayya BM, Sireesha M. Spectrophotometric determination of atorvastatin and ezetimibe using 2,4-dnp in bulk and pharmaceutical dosage forms. Int J Pharm Tech 2010;2:1046-56. Patel V, Baldha R, Patel D. Simultaneous determination of atorvastatin calcium and ezetimib by ratio spectra derivative spectrophotometry and reverse phase-high performance liquid chromatography. Asian J Chem 2010;22:2511-7. Chaudhari BG, Patel AB. Simultaneous spectrophotometric estimation of atorvastatin calcium and amlodipine besylate in tablet dosage forms. Int J Chem Tech Res 2010;2:633-9. Wankhede SB, Dixit NR, Chitlange SS. Validated spectrophotometric methods for quantitative determination of Atorvastatin calcium and Metoprolol succinate in Capsules. Pharm Chem 2010;2:134-40. Jadhav S, Bhatia M, Thamake S, Pishawikar S. Spectrophotometric methods for estimation of atorvastatin calcium form tablet dosage forms. Int J Pharm Tech Res 2010;2:1948-53. Rao L, Rajeswari KR, Sankar GG. Spectrophotometric method for simultaneous estimation of atorvastatin and amlodipine in tablet dosage form. Res J Pharm Biol Chem Sci 2010;1:975-85. Sharma S, Sharma MC. Method development and validation of atorvastatin calcium using FeCl3 by UV-visible spectrophotometric method. Am Eurasian J Toxicol Sci 2011;3:105-10. Havele OS, Havele SS. Simultaneous determination of atorvastatin calcium and pioglitazone hydrochloride in its multicomponent dosage forms by UV spectrophotometry. Int J Pharm Pharm Sci Res 2011;1:75-9. Sankar KAS, Vetrichelvan T, Venkappaya D. Simultaneous estimation of ramipril acetylsalicylic acid and atorvastatin calcium by chemometrics assisted UV-spectrophotometric method in capsules. Acta Pharm 2011;61:283–96. Savithri R, Sai Sree Bindu N, Shiva Bhargavi P, Theja DHH, Ramalingam P. Dual wavelength UV-spectrophotometric method for simultaneous estimation of atorvastatin and ezetimibe in bulk and their combined tablet dosage form. Pharm Sin 2011;2:251-8. Kumar Bada P, Kumar Sahu P, Abhinov T. Simple spectrophotometric methods for simultaneous determination of losartan potassium and atorvastatin calcium in combined dosage forms. J Chem Pharm Sci 2011;4:127-31. Prajapati KP, Bhandari A. Spectroscopic method for estimation of atorvastatin calcium in tablet dosage form. Indo Global J Pharm Sci 2011;1:294-9. Wani TA, Khalil NY, Abdel-Rahman HM, IA Darwish. Novel microwell-based spectrophotometric assay for determination of atorvastatin calcium in its pharmaceutical formulations. Chem Cen J 2011;5:1-8. Frag EYZ, Mohamed GG, Gaber MH. Sensitive extractive spectrophotometric method for the determination of some statin drugs in pharmaceutical preparations. Insight Pharm Sci 2011;1:39-46. Singh S, Inamullah, Rai J, Choudhary N, Sharma S. Stabilityindicating UV-vis spectrophotometric method for estimation of

23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35. 36. 37. 38. 39. 40.

Int J Pharm Pharm Sci, Vol 7, Issue 9, 427-433 atorvastatin calcium and fenofibrate in tablet dosage form. Bull Pharm Res 2012;2:159-66. Bernard S, Mathew M. Spectrophotometric method of estimation of atorvastatin calcium using sulfo-phospho-vanillin reaction. J Appl Pharm Sci 2012;2:150-4. Kane RN, Bhokare PS, Desai DS. Simultaneous spectrophotometric estimation of atorvastatin and fenofibrate in bulk drug and dosage form by using dual wavelength method. Int J Res Pharm Biomed Sci 2012;3:1448-53. Dey S, Sarkar S, Malakar J, Ghosh A, Gangopadhyay A, Mazumder B. Spectrophotometric method for simultaneous determination of atenolol and atorvastatin in tablet dosage forms. Int J Pharm Biomed Res 2012;3:40-3. Mateti A, Thimmaraju MK, Raghunandan N. Development, validation and estimation of atorvastatin calcium bulk and in its pharmaceutical formulation by spectrophotometric method. Int J Institutional Pharm Life Sci 2012;2:255-64. Belal T, Daabees H, Abdel-Khalek M, Mahrous M, Khamis M. New simple spectrophotometric method for determination of the binary mixtures (atorvastatin calcium and ezetimibe; candesartan cilexetil and hydrochlorothiazide) in tablets. J Pharm Anal 2013;3:118–26. Ghanty S, Sadhukhan N, Mondal A. Development and validation of a UV-spectrophotometric method for quantification of atorvastatin in tablets. J Pharm Sci Tech 2012;2:34-40. Sakpal PH, Deodhar MN, Ghodse VP, Agarwal BA, Khiste RH, Sonawane RA, et al. Simultaneous spectrophotometric estimation of ezetimibe and atorvastatin in Pharmaceutical dosage form. Int J Chem Sci 2012;10:131-6. Shariati-Rad M, Irandoust M, Amini T, Ahmadi F. Partial least squares and continuous wavelet transformation in Simultaneous spectrophotometric determination of amlodipin and Atorvastatine. Pharm Anal Acta 2012;3:2153-9. Inda SS, Sharma S, Das v, kumar B, bhandari A. First derivative spectrophotometric method for the estimation of atorvastatin calcium as bulk and in tablet dosage form. Int J Pharm Pharm Sci 2013;5:530-3. Erg˙in G, Ca˘glar S, ¨Onal A, Ert¨urk Toker S. Spectrophotometric determination of 3-hydroxy-3methylglutaryl coenzyme-A reductase inhibitors in pharmaceutical preparations. Turkish J Chem 2013;37:171–81. Sasikala M, Pravalika A, Bhaskar VU, Teja PH. Development and validation of UV spectrophotometric method for the simultaneous estimation of atorvastatin calcium and pioglitazone hydrochloride in tablet dosage form by derivative spectroscopic method. Int Bull Drug Res 2013;3:39-48. Bernard S, Mathew M, Senthilkumar KL, Girija KN. Simultaneous estimation of atorvastatin calcium and amlodipine besylate by uv spectrophotometric method using hydrotropic solubilization. Hygeia: J Drugs Med 2013;5:105-12. Rath K, Samantaray V, Dinda C. Development andvalidation of new analytical method for the estimation of atorvastatin calcium hydrate residue by using UV spectrophotometer. Int J Pharm Sci Res 2013;4:3416-24. Ramadan AA, Mandil H, Alshelhawi N. Spectrophotometric determination of rosuvastatin calcium in pure form and pharmaceutical formulations by the oxidation using iodine and formation triiodide complex in acetonitrile. Int J Pharm Pharm Sci 2014;6:579-85. Suma BV, Kannan K, Madhavan V, Chandini R. Nayar, Simultaneous estimation and validation of atorvastatin calcium and nicotinic acid in combined tablet dosage form by RP HPLC method. Int J Pharm Pharm Sci 2012;4:369-72. Shah Y, Iqbal Z, Ahmad L, Khan A, Khan MI, Nazir S, et al. Simultaneous determination of rosuvastatin and atorvastatin in human serum using RP-HPLC/UV detection: Method development, validation and optimization of various experimental parameters. J Chromatogr B 2011;879:557-63. Li Z, Deng YJ, Wang XM, Lei GF. HPLC determination of entrapment of coenzyme Q10. Chin J Pharm Anal 2006;26:149‐51. Jemat Z, Ouyang BC. Determination of pharmaceuticals in aquas samples using positive and negetive voltage switching

432

Ramadan et al.

41. 42. 43. 44.

45. 46. 47.

microbore liquid chromatography/electrospray ionisation tandem mass spectrometry. J Mass Spectrum 2003;38:27-34. Guihen E, Sisk GD, Scully NM, Glennon JD. Rapid analysis of atorvastatin calcium using capillary electrophoresis and microchip electrophoresis. Electrophoresis 2006;27:2338-47. Korany MA, Hewala II, Abdel-Hay KM. Determination of etofibrate, fenofibrate, and atorvastatin in pharmaceutical preparations and plasma using differential pulse polarographic and square wave voltammetric techniques. J AOAC Int 2008;91:1051-8. Erk N. Development of electrochemical methods for determination of atorvastatin and analytical application to pharmaceutical products and spiked human plasma. Crit Rev Anal Chem 2004;34:1–6. Dogan-Topal B, Uslu B, Ozkan SA. Investigation of electrochemical behavior of lipid lowering agent atorvastatin calcium in aqueous media and its determination from pharmaceutical dosage forms and biological fluids using borondoped diamond and glassy carbon electrodes. Comb Chem High Throughput Screening 2007;10:571–82. Dilek Eskiköy, Zehra Durmuş, Esma Kiliç. Electrochemical oxidation of atorvastatin and its adsorptive stripping determination in pharmaceutical dosage forms and biological fluids. Collect Czech Chem Commun 2011;76:1633-49. Ramadan AA, Mandil H, Hafez B. Differential pulse polarography of atorvastatin in pure and pharmaceutical dosage forms using static mercury drop electrode. Int J Pharm Pharm Sci 2013;5:434-40. Ramadan AA, Mandil H, Hafez B. Differential pulse polarographic determination of atorvastatin in pharmaceutical dosage forms using dropping mercury electrode. Asian J Chem 2013;25:3467-72.

Int J Pharm Pharm Sci, Vol 7, Issue 9, 427-433

48. Ramadan AA, Mandil H, Hafez B. Effect of hanging mercury drop electrode on differential pulse polarographic analysis of atorvastatin in pharmaceuticals using borax buffer at pH7.50. Int J Pharm Pharm Sci 2012;4(Suppl 5):540-6. 49. Labat P. Ph. D. Thesis, Electrochemical analysis of some toxic pollutants. Aleppo University, Aleppo, Syria; 1992. 50. Ramadan AA, Sabagh G. The effect of non-aqueous solvents on potentiometric titration of Cu(II) and Pb(II) by iodide and determination of pollution by copper and lead using ion selective electrodes. Res J Aleppo University 1994;17:93-12. 51. Edrees G. M. Sc. Thesis, High frequency titration of halogens in non-aqueous media, Aleppo University, Aleppo, Syria; 2005. 52. Ramadan AA, Agasyan PK, Petrov SI. Spectrophotometric and potentiometric study of formation I3-complex in mixture solvents. Gen Chem 1974;44:983-92. 53. Ramadan AA, Agasyan PK, Petrov SI. Spectrophotometric determination of formation constant I3-complex in some organic solvents. Gen Chem 1974;44:2299-07. 54. Ramadan AA, Agasyan PK, Petrov SI. Potentiometric titration of iodine by a thiosulphate solution in non-aqueous media and the formation of I3- complex ion. Zh Anal Khim 1973; 28: 2396-01. 55. Ramadan AA, Agasyan PK, Petrov SI. Effect of mixed solvents on determination of iodine by sodium thiosulphate solution with potentiometric detection of an end point. Zh Anal Khim 1974;29:544-50. 56. Ramadan AA, Ashur S. Spectophotometric determination of iodine and iodide, bromide and chloride by iodine in nonaqueous solvents and formation of polyhalogen complexes. Res J Aleppo Univ 1989;11:57-76. 57. Ramadan AA, Ashur S. Spectophotometric and potentiometric study of I2:Y-(Y-=I-or Br-or Cl-) complexes in non-aqueous solvents. Res J Aleppo Univ 1995;20:143-63.

433